% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • zake1 zake1 Jul 13, 2013 2:16 PM Flag

    From the JPM presentation

    This in it's entirety is available at the Investor Village board. And if you read the entire transcript, you will
    fast become aware of why the negative purveyors here do not want us in this stock..They are being beaten
    to keep the price down so accumulation can take place as fast as possible..The following is a small excerpt
    from the presentation.
    Why do we believe that ARIKACE is going to work? Typically, I tend to avoid invitro and invivo references but we've recently received so many designations and signs of support from the FDA . I'm often asked how did you secured those? So I share with you today for the first time some of the insides that we've seen from invitro and invivo studies that demonstrate the bactericidal side effect of ARIKACE on AVM complex. In this invitro study, you see a nice does response curve when ARIKACE is applied against these different strains of streams. And importantly in the low right hand corner here, you see statistically significant superiority to amikacin in the reduction in log CFU of Mac.

    So in the invitro vitro setting we're very excited by this data. I think. I think the FDA and key opinion leaders are as well it suggest that not only is it affective against the underlying pathogens but importantly in this model we didn't see any toxicity towards the lung either infected or otherwise uninfected. To augment that study, we looked at the effect of multiple inhaled doses of ARIKACE against mac in a mask model against IVM which is the standard of care right now used to treat NTM as I mentioned previously. ARIKACE , when it's administered every other day was numerically superior to daily administration of a dose of amikacin in injected form that is 25% higher in concentration

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.98+0.10(+1.01%)11:28 AMEDT